Stimulant

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Retrieved on: 
Monday, November 11, 2019

SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.

Key Points: 
  • SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.
  • In addition, we announced last week that we initiated a Phase III program to study SPN-812 in the adult ADHD patient population.
  • SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

New Jersey's Leading Drug and Alcohol Detox Program To Open A Freehold, New Jersey Location

Retrieved on: 
Wednesday, October 16, 2019

CNT is New Jersey's first licensed ambulatory (outpatient) detoxification program for all substances of abuse, including alcohol, anesthetics, benzodiazepines, opiates, stimulants and others.

Key Points: 
  • CNT is New Jersey's first licensed ambulatory (outpatient) detoxification program for all substances of abuse, including alcohol, anesthetics, benzodiazepines, opiates, stimulants and others.
  • Outpatient treatment delivers better outcomes by incorporating the living environment into treatment and engaging the patient's family in treatment.
  • If you or a loved one have a problem with drugs or alcohol now is the time to seek treatment.
  • Led by Board Certified Addiction Psychiatrist, Indra Cidambi, M.D., experienced physicians and nurses provide high-quality treatment.

The American College of Medical Toxicology Receives a $500,000 Grant to Expand Substance Use Disorder Curriculum

Retrieved on: 
Thursday, October 10, 2019

To expand the number of practitioners able to deliver high-quality, evidence-based substance use disorder (SUD) treatment, SUD education must be integrated into the standard curriculum of relevant healthcare and health services education programs.

Key Points: 
  • To expand the number of practitioners able to deliver high-quality, evidence-based substance use disorder (SUD) treatment, SUD education must be integrated into the standard curriculum of relevant healthcare and health services education programs.
  • The purpose of this grant program is to develop a high-quality, comprehensive curriculum to identify and treat patients with SUD.
  • The curriculum will include screening, assessment and treatment principles and their application, particularly regarding alcohol, marijuana, stimulants, and opioids.
  • The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology.

Players In The $2.26 Billion Biostimulants Market are Forming Strategic Alliances for Business Expansion | Report From TBRC

Retrieved on: 
Thursday, October 10, 2019

LONDON, Oct. 10, 2019 /PRNewswire/ -- Bio stimulants manufacturers are forming strategic alliances with other companies in the bio stimulants market to expand product portfolios and enter into new markets.

Key Points: 
  • LONDON, Oct. 10, 2019 /PRNewswire/ -- Bio stimulants manufacturers are forming strategic alliances with other companies in the bio stimulants market to expand product portfolios and enter into new markets.
  • Place a DIRECT PURCHASE ORDER Of Complete Report With TOC @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2516
    Major players in the global biostimulants market are BASF, Valagro, Bayer, Koppert Biological Systems and Italpollina.
  • Lack of awareness about bio stimulants and its usage among farmers is acting as a restraint on the bio stimulants market growth.
  • The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies.

Abuse Deterrent Formulation Technologies Market, 2030

Retrieved on: 
Monday, October 7, 2019

DUBLIN, Oct. 7, 2019 /PRNewswire/ -- The "Abuse Deterrent Formulation Technologies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 7, 2019 /PRNewswire/ -- The "Abuse Deterrent Formulation Technologies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • The 'Abuse-Deterrent Formulation Technologies Market, 2019-2030' report features an extensive study of the current market landscape and the future potential of industry players that are offering various abuse-deterrent formulation technologies to different pharmaceutical companies.
  • Moreover, opioid abuse was estimated to have been responsible for an economic deficit of over USD 500 billion, related to loss of productivity and healthcare costs, in the US.
  • Other drug classes that are prone to abuse include antidepressants and central nervous system (CNS) stimulants.

KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

Retrieved on: 
Tuesday, September 17, 2019

The Oppenheimer Fall Summit brings together the management teams from a select group of companies focused on specialty pharmaceuticals and orphan and rare diseases with investors to discuss therapeutic programs in development and recent corporate updates.

Key Points: 
  • The Oppenheimer Fall Summit brings together the management teams from a select group of companies focused on specialty pharmaceuticals and orphan and rare diseases with investors to discuss therapeutic programs in development and recent corporate updates.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

GTL Provides Access to Substance Abuse Behavioral Modification Resources to Assist Inmates in Rehabilitation

Retrieved on: 
Tuesday, July 30, 2019

Inmates face many barriers to treatment, including the lack of resources, infrastructure, and staff required to meet drug treatment needs.

Key Points: 
  • Inmates face many barriers to treatment, including the lack of resources, infrastructure, and staff required to meet drug treatment needs.
  • GTL offers the "Breaking Free from Substance Abuse" digital program via secure GTL Inspire tablets , allowing inmates to achieve and maintain recovery from dependence on over 70 different substances, including opioids, stimulants, prescribed medications, and alcohol.
  • The program also provides essential continuity since it follows inmates through the prison gate after release on probation or parole.
  • Now, through GTL's innovative technology, inmates with drug and alcohol problems across the United States can access this continuous, evidence-based behavioral support to assist their recovery and rehabilitation."

Global Central Nervous System (CNS) Stimulant Drugs Market Report 2019-2023 - Rising Demand to Legalize Cannabis Worldwide is a Key Market Driver - ResearchAndMarkets.com

Retrieved on: 
Monday, July 29, 2019

The "Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • This increasing prevalence of CNS disorders will lead to the expansion of the global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period.
  • The central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others.
  • With the presence of a few major players, the global central nervous system stimulant drugs market is concentrated.

The global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period

Retrieved on: 
Tuesday, July 23, 2019

This central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others.

Key Points: 
  • This central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others.
  • Our analysis also considers the sales of central nervous system stimulant drugs in Asia, Europe, North America, and ROW.
  • This increasing prevalence of CNS disorders will lead to the expansion of the global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period.
  • With the presence of a few major players, the global central nervous system stimulant drugs market is concentrated.

Athletes with ADHD May Take Longer to Recover from Concussion

Retrieved on: 
Friday, July 19, 2019

"Athletes with ADHD should be monitored with this in mind, as they may be more susceptible to prolonged recovery, and in general it's important to be aware of and address preexisting health conditions in anyone at risk for concussion."

Key Points: 
  • "Athletes with ADHD should be monitored with this in mind, as they may be more susceptible to prolonged recovery, and in general it's important to be aware of and address preexisting health conditions in anyone at risk for concussion."
  • The study used data from the NCAA-Department of Defense Grand Alliance: Concussion Assessment, Research, and Education (CARE) Consortium to evaluate 20 athletes with ADHD who were taking psychostimulant medications for ADHD, 20 athletes with ADHD who were not taking those medications, and 80 athletes who did not have ADHD.
  • The athletes were evaluated before the season started, within one-to-two days after the concussion and again when they were cleared to play with no restrictions.
  • All athletes with ADHD exhibited greater decreases in verbal memory and greater increases in symptom severity one-to-two days after concussion compared to the control athletes.